The excitement around the Pulse launch is valid, but let's focus on the numbers.
As of the September 2024 quarter, CDX had $546K in cash and was burning $3.14M per quarter. With $3.75M available in finance facilities, they have just over a quarter of funding left without new sales or additional capital raised.
CES is a great platform, but without real revenue growth and better cash management, the hype won’t last. Having a patent for an FDA-cleared home vascular health device is valuable, but the financials need to improve.
Q2 FY25 4C will show direction. If sales don’t pick up fast, further dilution is likely.
Add to My Watchlist
What is My Watchlist?
